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Abstract
Purpose Folic acid supplementation during pregnancy
has been associated with a reduced risk of common neu-
rodevelopmental delays in the offspring. However, it is
unclear whether low folate status has effects on the
developing brain. We evaluated the associations of
maternal folic acid supplementation and folate concentra-
tions during pregnancy with repeatedly measured prenatal
and postnatal head circumference in the offspring.
Methods Within a population-based prospective cohort,
we measured maternal plasma folate concentrations at
approximately 13 weeks of gestation (90 % range
10.5–17.2) and assessed folic acid supplementation by
questionnaire (2001–2005). Up to 11 repeated measures of
head circumference were obtained during foetal life (20
and 30 weeks of gestation) and childhood (between birth
and age 6 years) in 5866 children (2002–2012).
Results In unadjusted models, foetal head growth was
0.006 SD (95 % CI 0.003; 0.009, P\ 0.001) faster per
week per 1-SD higher maternal folate concentration. After
adjustment for confounders, this association was attenuated
to 0.004 SD per week (95 % CI 0.000; 0.007, P = 0.02;
estimated absolute difference at birth of 2.7 mm). The
association was independent of overall foetal growth. No
associations were found between maternal folate concen-
trations and child postnatal head growth. Preconceptional
start of folic acid supplementation was associated with
larger prenatal head size, but not with prenatal or postnatal
head growth.
Conclusions Our results suggest an independent, modest
association between maternal folate concentrations in early
pregnancy and foetal head growth. More research is needed
to identify whether specific brain regions are affected and
whether effects of folate on foetal head growth influence
children’s long-term functioning.
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Introduction
Supplementation with folic acid during embryonic devel-
opment reduces the risk of neural tube defects in infants [1,
2]. This protective effect has led to recommendations for
daily supplementation with folic acid starting preconcep-
tionally in women planning to become pregnant. Addi-
tionally, some countries have adopted fortification of flour
with folic acid [3].
Emerging evidence from observational research has
shown that maternal folic acid supplementation during
pregnancy is associated with reduced risk of several other
neurodevelopmental disorders in offspring, including lan-
guage delays [4], autism spectrum disorders [5, 6] and
problem behaviour [7]. However, the underlying neurobi-
ology of low folate and these neurodevelopmental prob-
lems remains unclear. Folic acid supplement use is strongly
related to higher socioeconomic status and is a marker of
good health literacy [8, 9], which increases the suscepti-
bility for confounding.
To further support a potential relationship between folic
acid supplement use and neurodevelopmental disorders,
nutritional biomarkers and biological intermediates can be
examined. Blood folate concentration serves as a key
nutritional biomarker. This can be measured in maternal
blood and can serve as the endpoint of the determinants of
folate status, i.e. after physiological absorption of folic acid
supplements and folates from natural (or fortified) foods
[10]. Unlike folic acid supplementation, folate concentra-
tions are unaffected by recall bias, thus serving as a better
proxy for actual folate status.
Biological intermediates include structural alterations in
the brain throughout pregnancy and early postnatal devel-
opment. Head circumference (HC) can serve as a non-in-
vasive and inexpensive proxy for foetal and early postnatal
brain growth and development. HC is closely related to
brain volume, particularly in the period before the skull is
fully developed [11, 12]. Several neurodevelopmental
disorders are associated with subtle changes in head
growth. Children with autism for instance have normal to
slightly smaller HC at birth, followed by accelerated head
growth in the first year of life when compared to non-
autistic children [13].
Folate is involved in a number of essential processes of
growth and development, such as DNA synthesis and gene
expression. Consequently, folate requirements are increased
in periods of rapid growth, such as pregnancy. Low maternal
folate concentrations directly limit the availability of folate
to the foetal cells, which results in impairment of cell divi-
sion and potentially impairs growth [14].
Earlier research provides inconsistent evidence for an
association between maternal folate concentrations and HC
at birth, and no evidence for an association between
maternal folic acid supplementation and HC at birth [15].
In a previous report of the current cohort, maternal folic
acid supplementation was associated with head size in
prenatal life, but foetal head growth was not considered as
a pregnancy outcome [16]. Whether prenatal folate con-
centrations or maternal folic acid supplementation during
pregnancy has sustained or additive effects on postnatal
head growth is unknown.
We used the Generation R cohort to evaluate the asso-
ciations of both maternal folic acid supplementation and
folate concentrations during pregnancy with repeatedly
measured offspring prenatal and postnatal head size. We
hypothesised that folic acid supplementation as well as
higher folate concentrations is associated with increased
head growth in the offspring.
Methods
Study population
The subjects were participants in the Generation R Study, a
population-based cohort from early foetal life onwards in
Rotterdam, the Netherlands [17]. The study was conducted
in accordance with the guidelines proposed in the World
Medical Association Declaration of Helsinki and was
approved by the local medical ethics committee. Written
consent was obtained from all participants.
In total, 8879 women were enrolled in the Generation R
Study during pregnancy. Out of 8782 women with a sin-
gleton pregnancy, 6993 women (80 %) enrolled in the
study before 18 weeks of gestation. We measured plasma
folate concentration in early pregnancy in 5965 (85 %) of
these women. We excluded 37 women since their measure
of folate was above the assay range, resulting in valid
folate concentrations at baseline for 5928 mothers. Twenty
children died during the neonatal period and one was lost to
follow-up before birth; these were excluded from this
study. In total, at least one measure of foetal or child HC
was obtained in 5866 children.
Maternal folic acid supplement use
Before 18 weeks of gestation (median 13.2 weeks; 90 %
range 10.5–17.2 weeks), pregnant women were asked by
questionnaire whether they used folic acid supplements or
multivitamin preparations and when they started supple-
mentation. In the Netherlands, both folic acid supplements
and multivitamin preparations for pregnant women contain
400–500 lg folic acid; there is no mandatory food fortifi-
cation with folic acid. In line with previous publications,
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we categorised folic acid supplement use in four groups:
(1) preconceptional start (as recommended [18])
(n = 2153), (2) start within the first 10 weeks of pregnancy
(n = 1602), (3) start after the first 10 weeks of pregnancy
(n = 753) and (4) no use (n = 1358) [19]. To distinguish
between effects of folic acid and multiple micronutrients,
we separated preconceptional start into ‘folic acid only use’
(n = 1396) and ‘multivitamin use’ (n = 757) in additional
analyses.
Maternal folate concentrations
In early pregnancy (median 13.2 weeks; 90 % range
10.5–17.2 weeks), venous blood samples were drawn,
centrifuged and stored at -80 C, as previously described
[20]. After thawing, folate concentrations were analysed in
2008, using an immunoelectrochemoluminence assay. The
between-run coefficients of variation for plasma folate
varied between 1.5 and 8.9 %, with an analytic range of
1.8–45.3 nmol/L (0.8–20.0 ng/mL).
Folate concentration was analysed:
(a) as a continuous variable (standard deviation scores
(SDS)) and
(b) as a dichotomous variable, categorised into ‘folate-
deficient’ (\7 nmol/L = 3.1 ng/mL, 8.4 %) [10] or
‘normal folate concentration’.
Additional analyses were performed using a different
cut-off (based on normative concentrations determined by
the Erasmus Medical Centre laboratory: cut-off\8 nmol/L
(3.5 ng/mL); 13.8 %).
Foetal and child head circumference
Foetal ultrasound measurements were performed at pre-
natal visits during each trimester of pregnancy [17, 21].
First trimester ultrasounds were primarily used for preg-
nancy dating [21, 22]. The intra- and interobserver relia-
bilities of foetal biometry in early pregnancy were
excellent (all intra-class correlation coefficients greater
than 0.98) [23].
HC was subsequently measured at birth and in up to
seven visits at child healthcare centres at the ages of 0–2, 2,
3, 4, 5–10, 10–13 and 13–17 months. Gender of the child
and gestational age at birth were extracted from medical
records. HC was again measured at the Generation R
research centre (mean age of 6.2 years).
Gender and gestational age-adjusted SD scores were
constructed for all measures of HC based on growth ref-
erence curves [21, 24]. This approach enables linear anal-
yses of (nonlinear) growth patterns [25].
Covariates
Several maternal and child characteristics were selected as
possible confounding variables, based on previous studies
of maternal folate or foetal development [15, 26]. These
were maternal age and body mass index (BMI) at enrol-
ment, national origin, educational level, smoking and
alcohol consumption during pregnancy, psychopathology
in mid-pregnancy (highest prevalence for anxious and
depressive symptoms), parity, family income, foetal/child
gender and gestational age at time of the HC measure-
ments. Assessment of these covariates has been described
in detail previously [19, 26, 27].
Statistical analyses
Folic acid supplementation and folate concentration were
used as the independent variables in the analyses. In the
analyses of folic acid supplementation, the group of
mothers who did not use folic acid supplements comprised
the reference group. In the analyses of folate deficiency, the
group of mothers with normal folate concentrations com-
prised the reference group. We additionally used linear
regression models to evaluate the associations between
maternal folate concentrations with offspring head size at
all separate time points of HC measurement.
To test the associations with offspring head growth, we
performed longitudinal analyses using unbalanced repeated
measures analysis (mixed models). These analyses were
performed separately for prenatal and postnatal head
growth, since growth patterns as well as measurement
methods differ between these developmental stages. Using
maternal folate concentration as the independent variable,
the model can be written as follows:
SD score of HC ¼ b0 þ b1  gawksþ b2  folate
þ b3  gawks  folate þ e
(b0 = intercept; gawks = gestational age in weeks; e
includes additional covariates for the adjusted model and
error; similarly, a formula for folic acid supplementation as
the independent variable can be defined). The term ‘b2 -
9 folate’ tests the difference in intercept for each 1-SD
higher folate concentration or comparing the folate-defi-
cient group to the reference group. Gestational age was
centred at 20 weeks of gestation in the prenatal models.
Coefficient b3 reflects the slope (interaction of gesta-
tional age and folate) and represents the average decline or
increase in head growth per gestational week for each 1-SD
higher folate concentration or in children of folate-deficient
mothers versus the reference group. Thus, the weekly
change in the SD score is multiplied by the average number
Eur J Nutr (2017) 56:65–75 67
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of weeks of pregnancy to obtain the expected difference at
birth. A random-effects model was applied for the intercept
and gestational age to account for within- and between-
individual variation. All other covariates were fitted as
fixed effects. Longitudinal analyses were additionally
adjusted for the effects of maternal ethnicity, smoking and
educational level on head growth per week [28–31]. We
also added a quadratic term of the continuous folate vari-
able to test for nonlinear associations. Additionally, to
further explore nonlinearity and potential effects of very
high folate status, we (1) divided maternal folate concen-
tration into quintiles and (2) compared the highest 10 %
(folate[ 30.2 nmol/L, n = 588) and 5 % (fo-
late[ 33.8 nmol/L, n = 292) of the distribution of folate
concentrations with the remaining 90 and 95 %, respec-
tively, in secondary analyses.
Basic models were adjusted for gestational age at
venipuncture, and gender and age of the foetus/child at
assessment, if applicable. Subsequent models were addi-
tionally adjusted for the covariates mentioned earlier.
Further, in the event of a significant association, we addi-
tionally adjusted for estimated foetal weight (EFW) to test
whether maternal folic acid supplementation or folate sta-
tus specifically affects offspring HC size/growth indepen-
dent of overall growth. Finally, we explored potential
effect modification by child gender in the fully adjusted
models by including the interaction term between maternal
folic acid use/folate concentration and child gender.
Missing values of covariates were imputed using the
Markov Chain Monte Carlo multiple imputation technique
with predictive mean matching for continuous variables
(0.1–21.4 % missing data). Five imputed datasets were
generated. Subsequently, analyses were performed sepa-
rately on each completed dataset and thereafter combined
to one pooled estimate.
Results
Descriptive characteristics of the participating mothers and
their children are presented in Table 1.
Maternal folic acid supplementation and offspring
head circumference
Table 2 shows the analyses of the association of maternal
folic acid supplementation with offspring head size and
growth. In the basic model, foetuses of mothers who started
folic acid supplementation before conception or within
10 weeks of pregnancy had a slightly larger head size at
20 weeks of gestation compared with children of mothers
who did not use supplements during pregnancy. After
adjustment for confounders, this association was only
observed in foetuses of mothers who started supplemen-
tation before conception, similar to the previous report
[16]. Maternal ethnic background, income, BMI at enrol-
ment and smoking during pregnancy were the main con-
founders. Additional adjustment for EFW slightly
attenuated the effect estimate, but the association remained
statistically significant (B = 0.112, 95 % CI 0.028; 0.196,
P\ 0.01).
We found no evidence for an association between
maternal folic acid supplementation during pregnancy and
prenatal or postnatal head growth in the offspring
(Table 2).
With regard to potential effect modification, none of the
interaction terms of maternal folic acid use with child
gender (either in pre- or postnatal models) were statistically
significant (all P values[ 0.10). Therefore, analyses were
not further stratified by gender.
The effect of supplement use could not be attributed to
other nutrients in the supplement: foetuses of mothers who
started using any supplement before conception had a lar-
ger HC size at 20 weeks of gestation than those whose
mother did not use supplements (fully adjusted models:
B‘preconceptional start folic acid’ vs ‘no use’ = 0.131, 95 % CI
0.031; 0.232, P = 0.01; B‘preconceptional start multivitamins’ vs
‘no use’ = 0.115, 95 % CI 0.009; 0.221, P = 0.03). After
additional adjustment for EFW, the latter association of
maternal preconceptional multivitamin use with foetal HC
size disappeared (B = 0.097, 95 % CI -0.005; 0.198,
P = 0.06), whereas the association of preconceptional folic
acid use with foetal HC size did not (B = 0.120, 95 % CI
0.025; 0.216, P = 0.01).
Maternal folate concentrations and offspring head
circumference
The first part of Table 3 shows the analyses of the asso-
ciations of maternal folate concentrations with offspring
head size. At 20 weeks of gestation, neither folate SD
scores nor folate deficiency was associated with head size.
In the basic linear regression models, higher maternal
folate concentration was associated with a larger child head
size at 20 and 30 weeks of gestation, at birth, at age
5–10 months and at 6 years (see Online Resource 1; note:
size here in mm). Only at 30 weeks of gestation, this
association was not accounted for by confounders. Addi-
tional adjustment for EFW attenuated the effect estimate,
but the association remained statistically significant
(B = 0.27, 95 % CI 0.03; 0.51, P = 0.03). Including
quadratic terms of folate to the model did not improve the
fit (data not shown). When using folate as a dichotomous
variable, no associations were found between folate defi-
ciency and offspring head size. Similar results were found
using 8 nmol/L to define low maternal folate status.
68 Eur J Nutr (2017) 56:65–75
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The associations of maternal folate concentrations with
offspring head growth are presented in Table 3. Higher
maternal folate concentrations were associated with increased
foetal head growth, and folate deficiency was associated with
decreased foetal head growth in the basic models. These
associations were attenuated when fully adjusted for
Table 1 Subject characteristics
by maternal folate deficiencya in
early pregnancyb
Folate-deficient
n = 493 (8.4 %)
Normal folate concentrations
n = 5373 (91.6 %)
Pc
Child characteristics
Gender (% girl) 49.5 47.8 0.50
Gestational age at birth (weeks)d,e 39.7 ± 2.2 39.9 ± 1.7 \0.01
Maternal characteristics
Age at enrolment (years) 27.0 ± 5.5 30.0 ± 4.9 \0.001
Gestational age at enrolment (weeks)f 14.3 ± 2.2 13.5 ± 2.0 \0.001
Ethnicity (%)
Dutch 28.9 53.9
Other Western 7.1 9.0
Turkish or Moroccan 24.8 13.7 \0.001
Surinamese or Antillean 21.1 10.6
Other non-Western 18.1 12.8
Education (%)
Higher 14.5 45.8
Secondary 62.7 44.5 \0.001
Primary 22.8 9.7
Family income (%)
[2000 €/month 23.9 60.7
1200–2000 €/month 25.5 19.6 \0.001
\1200 €/month 50.6 19.7
BMI at intake (kg/m2) 25.5 ± 5.0 24.4 ± 4.3 \0.001
Smoking during pregnancy (%)
Never 62.3 75.4
Until pregnancy was known 6.0 8.5 \0.001
Continued throughout pregnancy 31.7 16.1
Alcohol consumption during pregnancy (%)
Never 62.2 43.7
Until pregnancy was known 13.5 14.1 \0.001
Continued throughout pregnancy 24.3 42.2
Parity, primiparae (%) 42.8 58.4 \0.001
Psychopathology in mid-pregnancyg 0.42 ± 0.47 0.28 ± 0.37 \0.001
Folic acid supplement use during pregnancy (%)
No use 72.5 18.6
Start[ 10 weeks pregnancy 11.0 13.0 \0.001
Start B 10 weeks pregnancy 10.0 28.9
Preconceptional start 6.5 39.5
a Folate deficiency was defined as a folate concentration\7 nmol/L
b Descriptives on imputed data
c Derived from linear regression analysis for continuous variables or logistic regression analysis for cat-
egorical variables on imputed data
d Means ± SD (all such values)
e Median (95 % range): deficient group: 39.9 (34.4–42.3); nondeficient group: 40.1 (35.8–42.3)
f Median (95 % range): deficient group: 14.4 (9.8–17.8); nondeficient group: 13.2 (9.6–17.5)
g Median (95 % range): deficient group: 0.25 (0.0–1.92); nondeficient group: 0.15 (0.0–1.39)
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confounders (main confounders: maternal ethnic background,
income, BMI at enrolment and smoking during pregnancy).
However, foetuses exposed to higher maternal folate con-
centrations in early pregnancy (continuous measure) showed
increased head growth between the second and third trimester
of pregnancy: for each 1-SD higher folate concentration,
foetal head growth was 0.004 SD per week faster, even after
additional adjustment for EFW (95 % CI 0.000; 0.007,
P = 0.02). This results in an average estimated increase of
0.16 SD at birth, which translates into approximately 2.7 mm
difference in HC at birth.
Again, including quadratic terms of folate to the
model did not improve the fit (data not shown). In
secondary analyses, maternal folate concentration was
divided into quintiles, using the lowest quintile as the
reference category (quintile 1). In a dose–response
manner, foetuses of mothers with a folate concentration
in the second through highest quintile had significantly
greater prenatal head growth compared to foetuses of
mothers with a folate concentration in the lowest quin-
tile, although this difference was only statistically sig-
nificant for those children of mothers with a folate
Table 2 Maternal folic acid supplementation during pregnancy and offspring head size at 20 weeks of gestation, prenatal head growth and
postnatal head growtha
Head circumference size (SDS)
Basicb Adjusted for covariatesc
SDSd Be (95 % CI) P SDSd Be (95 % CI) P
Head size (intercept (SDS) at 20 weeks gestation) and folic acid supplementation (n = 5832 (99.4 %), 11,323 observations)
No usef 20.163 Reference 20.003 Reference
Start[ 10 weeks 20.135 0.028 (20.069; 0.126) 0.57 20.004 20.001 (20.104; 0.101) 0.98
Start B 10 weeks 20.075 0.088 (0.011; 0.166) 0.03 0.028 0.031 (20.054; 0.115) 0.48
Preconceptional start 0.058 0.221 (0.147; 0.296) \0.001 0.123 0.126 (0.037; 0.215) \0.01
Head circumference growth (SDS)
Basicb Adjusted for covariatesc
Bg (95 % CI) P Bg (95 % CI)) P
Period of head growth and folic acid supplementation
Second and third trimester (n = 5832 (99.4 %), 11,323 observations)
No usef Reference Reference
Start[ 10 weeks 0.002 (20.008; 0.012) 0.72 0.001 (20.009; 0.011) 0.84
Start B 10 weeks 0.004 (20.004; 0.012) 0.31 0.002 (20.007; 0.010) 0.69
Preconceptional start 0.008 (20.000; 0.016) 0.05 0.002 (20.007; 0.012) 0.65
Birth through 6 years (n = 5515 (94.0 %), 29,976 observations)
No usef Reference Reference
Start[ 10 weeks 20.000 (20.000; 0.000) 0.32 20.000 (20.000; 0.000) 0.26
Start B 10 weeks 20.000 (20.000; 0.000) 0.45 20.000 (20.000; 0.000) 0.39
Preconceptional start 20.000 (20.000; 0.000) 0.15 20.000 (20.000; 0.000) 0.26
SDS standard deviation score
a Gender and gestational age-adjusted foetal and child head circumference standard deviation scores
b Model 1: no adjustments
c Model 2: model 1, additionally adjusted for maternal age, ethnicity, education, income, parity, BMI, psychopathology, smoking and alcohol
consumption during pregnancy and the interactions between gestational age and maternal smoking, ethnicity and education
d Values represent offspring head size in SDS at 20 weeks of gestation (intercept) per group of folic acid supplementation
e Values represent B (95 % CI) for the difference in offspring head size (intercept) for each group of folic acid supplementation compared with
the reference group of ‘no use’ from mixed model regression analyses
f Reference group of primiparae women who never smoked or drank alcohol during pregnancy, with mean age of 29.8 years and mean BMI of
24.5 at enrolment, Dutch national origin, higher education, family income[ € 2000/month and median Global Severity Index score of 0.17 in
mid-pregnancy
g Values represent B (95 % CI) for the interaction between maternal folic acid supplementation and gestational age (in weeks) from mixed
model regression analyses, i.e. the difference in offspring head circumference growth (in SDS) per week for each group of folic acid supple-
mentation compared with the reference group of ‘no use’
70 Eur J Nutr (2017) 56:65–75
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concentration in the highest quintile (B = 0.012,
P = 0.018, see Online Resource 2; P for trend = 0.018).
However, we did not observe greater foetal head growth
in foetuses of mothers with a folate concentration in the
extreme high ends of the folate distribution (Bhigh-
est 10 % folate = 0.002, P = 0.64; Bhighest 5 % folate = 0.003,
P = 0.69) compared with foetuses of mothers with
a folate concentration in the remainder of the
distribution.
No associations were found between maternal folate
concentrations or folate deficiency and postnatal head
growth. These results did not change after exclusion of the
birth measure of HC, which can be highly imprecise due to
the moulding that takes place during the birth process.
Table 3 Maternal folate concentrationa/deficiencyb during pregnancy and offspring head size at 20 weeks of gestation, prenatal head growth and
postnatal head growthc
Head circumference size (SDS)
Basicd Adjusted for covariatese
SDSf Bg (95 % CI) P SDSf Bg (95 % CI) P
Head size (intercept (SDS) at 20 weeks gestation) and folate concentration (n = 5832 (99.4 %), 11,323 observations)
Mean folateh,i 20.055 Reference 0.074 Reference
Folate (per SD)j 20.021 0.034 (0.007; 0.061) 0.01 0.081 0.007 (20.022; 0.037) 0.63
Normal folatei 20.051 Reference 0.077 Reference
Folate-deficient 20.100 20.049 (20.148; 0.049) 0.32 0.110 0.033 (20.068; 0.134) 0.52
Head circumference growth (SDS)
Basicd Adjusted for covariatese
Bk (95 % CI) P Bk (95 % CI) P
Period of head growth and folate concentration
Second and third trimester (n = 5832 (99.4 %), 11,323 observations)
Folate (per SD)h,i 0.006 (0.003; 0.009) \0.001 0.004 (0.001; 0.007) 0.01
Folate-deficient 20.013 (20.023; 20.002) 0.02 20.007 (20.018; 0.004) 0.19
Birth through 6 years (n = 5515 (94.0 %), 29,976 observations)
Folate (per SD)h,i 20.000 (20.000; 0.000) 0.28 20.000 (20.000; 0.000) 0.66
Folate-deficient 0.000 (20.000; 0.001) 0.06 0.000 (20.000; 0.000) 0.29
SDS standard deviation score
a Folate concentration in standard deviation scores
b Folate deficiency was defined as a folate concentration\ 7 nmol/L. Subjects without folate deficiency comprised the reference group ‘normal
folate’
c Gender and gestational age-adjusted foetal and child head circumference standard deviation scores
d Model 1: adjusted for gestational age at venipuncture
e Model 2: model 1, additionally adjusted for maternal age, ethnicity, education, income, parity, BMI, psychopathology, smoking and alcohol
consumption during pregnancy and the interactions between gestational age and: maternal smoking, ethnicity and education
f Values represent offspring head size in SDS at 20 weeks of gestation (intercept) per type of folate concentration from mixed model regression
analyses
g Values represent B (95 % CI) for the difference in offspring head size (intercept) for each type of folate concentration compared with its
reference (‘mean folate’ or ‘normal folate’) from mixed model regression analyses
h Mean folate concentration: 0 SDS : 17.4 nmol/L
i Reference group of primiparae women who never smoked or drank alcohol during pregnancy, with mean age of 29.8 years and mean BMI of
24.5 at enrolment, Dutch national origin, higher education, family income[ € 2000/month and median Global Severity Index score of 0.17 in
mid-pregnancy
j Standard deviation folate concentration: 8.8 nmol/L
k Values represent B (95 % CI) for the interaction between maternal folate concentration/deficiency and gestational age (in weeks) from mixed
model regression analyses, i.e. the difference in head circumference growth (in SDS) per week for each SD increase in folate concentra-
tion/between children of mothers with and without folate deficiency
Eur J Nutr (2017) 56:65–75 71
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Again, none of the interaction terms of maternal folate
concentration with child gender (either in pre- or postnatal
models) were statistically significant (all P values[0.10),
and analyses were not further stratified by gender.
Discussion
In this population-based study, we found small effects of
maternal folic acid supplementation and folate concentra-
tion on head growth in the offspring. Maternal precon-
ceptional start of folic acid supplementation was associated
with larger prenatal head size at 20 weeks of gestation, but
not with prenatal head growth after week 20 or postnatal
head growth. Maternal folate concentrations—serving as
nutritional biomarkers—were related to a faster foetal head
growth from the second to the third trimester of pregnancy,
resulting in a larger head size at 30 weeks of gestation. The
associations were independent of overall foetal growth.
Although the direction of the associations between very
low or high folate status and foetal head growth was in line
with those from analyses with the continuous measure of
folate, our results suggest a linear effect of folate on HC
rather than extremely low or high folate concentrations
driving the association. No effect of maternal folate on HC
was observed after birth.
Folic acid supplementation versus folate
concentrations
Folic acid supplement use and folate concentrations are
correlated, but their correlation is moderate; the quantita-
tive relationship between supplement and biomarker is
influenced by various physiological and environmental
factors [32]. Folate concentrations are more directly related
to the biological processes in the human body than self-
reported folic acid use. As such, they are a more precise
measure of actual folate status, allowing for better detec-
tion of potential subtle effects. This may explain why
maternal folate concentrations were associated with off-
spring head growth, whereas folic acid supplementation
was not. Alternatively, in contrast to the categorical
approach of folic acid supplementation, a continuous
measure of folate concentration has statistically more
power to detect differences.
In addition, although we measured folic acid supple-
mentation retrospectively early in pregnancy, it covers the
preconceptional period, whereas folate concentrations were
measured around 13 weeks of gestation. Our measurements
of HC started at 20 weeks of gestation. Since foetuses of
mothers who preconceptionally started folic acid supple-
mentation had a larger HC at 20 weeks of gestation com-
pared to those whose mothers did not use folic acid, the
effect of supplementation may already have occurred
before 20 weeks of gestation.
Prenatal versus postnatal head growth
We observed an association between maternal folate con-
centrations and offspring head growth prenatally, but not
postnatally. Schlotz et al. [33] reported an association
between maternal folate concentration measured at the
same gestational age as in the current study (13.5 weeks)
and HC at birth, but not 9 months after birth, concluding
that maternal folate specifically affects prenatal head
growth. Our findings of specific effects of maternal folate
on foetal head growth, independent of overall growth,
support and extend this conclusion. A plausible explanation
may be the relatively close proximity of foetal HC mea-
sures to the measure of folate concentrations early in
pregnancy, in contrast to the more distant measures of child
HC. Additionally, small prenatal effects on head size may
be compensated in postnatal life, when other factors can
modulate neurodevelopment and brain plasticity, such as
child nutrition and enriched environments. Further, animal
studies have shown that folate can affect both embryonic
and foetal brain development at various stages, including
cell proliferation and differentiation, through epigenomic
effects [34]. While the effect sizes we observed are mar-
ginal, small effects on head growth during prenatal life
may have, for example, an exponential effect on the
number of synaptic connections, which can influence the
overall connectivity and plasticity potential of the devel-
oping brain. Each cortical neuron has on average between
1000 and 10,000 synapses. Thus, a small reduction in
neurons can have a very large effect on the number of
connections within the brain. This in turn may predispose
the child to cognitive and behavioural impairment later in
life. Such subtle changes in brain development, however,
cannot be accurately measured postnatally with a simple
proxy like HC. To improve measurement accuracy, alter-
native measures, such as brain MRI, will need to be used.
Residual confounding
Residual confounding can never be excluded as an expla-
nation for observed associations in epidemiological studies.
Lifestyle and socio-economic factors are strongly related to
folic acid supplement use, but also affect overall dietary
intake and health status. This is reflected in the current
study by the fact that folate-deficient women differed on
many of these factors from women with a plasma folate
concentration in the normal range. A decline in the effect
of maternal folate concentration on foetal HC size and
growth was noticeable after adjustment for confounders.
Biomarkers providing information about supplement use
72 Eur J Nutr (2017) 56:65–75
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can be confounded although they do not rely on self-report
data and are thus less prone to information bias. Further
(residual) confounding, for example in terms of other
nutrients in the diet, cannot be excluded.
Strengths and limitations
The strengths of our study are its large sample size,
availability of plasma folate concentrations as opposed to
dietary intake of folate, having multiple measures of off-
spring HC (starting in pregnancy) and the ability to adjust
for a considerable number of covariates.
The study also has its limitations. First, our assessment
of maternal folate status was based on a single measure in
blood plasma. One measurement, although indicative, is
not a reliable reflection of a mother’s long-term folate
status. Additionally, red blood cell instead of plasma folate
would be a better measure of long-term folate status. On
the other hand, plasma folate can be more reliably mea-
sured than red blood cell folate, as the serum/plasma folate
assay is less complex to perform and requires less steps in
handling the sample before analysis than the red cell folate
assay [35, 36]. To identify the most folate-sensitive win-
dow of foetal head growth, repeated measures of folate
concentrations throughout pregnancy are needed. Further,
ultrasound measures provide a global measure of brain
growth and development and do not have the contrast to
determine differences in cortical and subcortical develop-
ment, development of the cortical sheet, or myelination.
Prenatal MRI measurements could identify whether growth
differences are global or involve specific brain regions.
Relevance
Higher maternal folate concentrations were associated with
slightly increased foetal head growth from the second to
the third trimester. Additionally, preconceptional start of
folic acid supplementation was associated with a larger
head size at 20 weeks of gestation. In the Netherlands, only
about half of the women use folic acid supplements during
the conceptional period [18, 37, 38], and median dietary
folate equivalent intake from foods and supplements ranges
from 249 to 282 lg/day for women in reproductive age.
Within the same population, median dietary folate equiv-
alent intake from foods only ranges from 216 to
242 lg/day [39]. Whereas those women not using folic
acid supplements in the conceptional period may consume
enough folate from foods in order to prevent folate defi-
ciency, they do not meet the recommended daily intake of
400 lg of folate. Although folic acid fortification could
improve folate status, it would not provide the full
requirement. It thus remains important to better educate
women of childbearing age about the benefits of folic acid
supplementation. Additionally, more research is needed to
identify (1) the most folate-sensitive period of foetal head/
brain growth, (2) whether specific brain regions are affec-
ted and (3) whether the effects of folate on foetal head
growth influence children’s long-term functioning.
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